Continue to site >
Trending ETFs

Name

As of 03/15/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$21.87

$125 M

0.00%

1.13%

Vitals

YTD Return

6.9%

1 yr return

12.0%

3 Yr Avg Return

-2.7%

5 Yr Avg Return

3.8%

Net Assets

$125 M

Holdings in Top 10

53.3%

52 WEEK LOW AND HIGH

$21.9
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 1.13%

SALES FEES

Front Load 5.25%

Deferred Load N/A

TRADING FEES

Turnover 152.78%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$1,000

IRA

$500


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 03/15/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$21.87

$125 M

0.00%

1.13%

AHSAX - Profile

Distributions

  • YTD Total Return 6.9%
  • 3 Yr Annualized Total Return -2.7%
  • 5 Yr Annualized Total Return 3.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.63%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Alger Health Sciences Fund
  • Fund Family Name
    Alger Family of Funds
  • Inception Date
    May 01, 2002
  • Shares Outstanding
    N/A
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Daniel Chung

Fund Description

The Manager believes companies undergoing Positive Dynamic Change offer the best opportunities. Positive Dynamic Change refers to companies realizing High Unit Volume Growth or companies undergoing Positive Lifecycle Change. High Unit Volume Growth companies are traditional growth companies experiencing, for example, rapidly growing demand or market dominance. Positive Lifecycle Change companies are, for example, companies benefitting from new regulations, a new product innovation or new management.Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. Equity securities include common or preferred stocks that are listed on U.S. or foreign exchanges. A company will be considered to be engaged in the health sciences sector if it derives at least 50% of its earnings or revenues from, or devotes at least 50% of its assets to, activities in any area of the health sciences sector, including health care services, pharmaceuticals, medical equipment and supplies and applied research and development. Such companies include, but are not limited to:hospitals, clinical test laboratories, convalescent and mental health care facilities, home care providers, and companies that supply services to any of the foregoing;companies involved in pharmaceuticals, biotechnology, biochemistry and diagnostics; andproducers and manufacturers of medical, dental and optical supplies and equipment.The Fund may invest a substantial portion of its assets in a smaller number of issuers. Fund holdings may occasionally increase or decrease for a variety of reasons, including, among others, because of extreme market volatility, such as when the Fund has entered a temporary defensive position.  Additionally, the Fund may exceed its current number of holdings when it acquires a new holding and determines that it is in the best interests of shareholders to sell an existing holding over a period of time, instead of immediately selling the entire holding.The Fund may sell a stock when it reaches a target price, it fails to perform as expected, or other opportunities appear more attractive. As a result, the Fund may engage in active trading of portfolio securities.The Fund can also invest in privately placed securities, which are securities acquired in non-public offerings for which there is no readily available market.The Fund can invest in foreign securities.The Fund invests in cash (and cash equivalents) when the Fund is unable to find enough attractive long-term investments to meet its investment objective, to meet redemptions and/or when the Manager believes it is advisable to do so during times of short-term market volatility. During these times, cash (and cash equivalents) will not exceed 15% of the Fund’s net assets.
Read More

AHSAX - Performance

Return Ranking - Trailing

Period AHSAX Return Category Return Low Category Return High Rank in Category (%)
YTD 6.9% -13.3% 20.7% 28.22%
1 Yr 12.0% -19.1% 38.0% 70.55%
3 Yr -2.7%* -31.4% 13.8% 79.49%
5 Yr 3.8%* -3.8% 14.2% 80.15%
10 Yr 4.0%* -0.7% 13.8% 92.52%

* Annualized

Return Ranking - Calendar

Period AHSAX Return Category Return Low Category Return High Rank in Category (%)
2023 -4.3% -12.6% 19.0% 88.34%
2022 -17.0% -53.9% 3.2% 78.21%
2021 -19.8% -39.6% 24.2% 85.26%
2020 17.1% -13.6% 178.2% 33.77%
2019 14.0% 3.8% 63.8% 86.67%

Total Return Ranking - Trailing

Period AHSAX Return Category Return Low Category Return High Rank in Category (%)
YTD 6.9% -13.3% 20.7% 28.22%
1 Yr 12.0% -19.1% 38.0% 70.55%
3 Yr -2.7%* -31.4% 13.8% 79.49%
5 Yr 3.8%* -3.8% 14.2% 80.15%
10 Yr 4.0%* -0.7% 13.8% 92.52%

* Annualized

Total Return Ranking - Calendar

Period AHSAX Return Category Return Low Category Return High Rank in Category (%)
2023 -4.3% -12.6% 19.0% 92.02%
2022 -17.0% -53.9% 3.7% 83.33%
2021 2.5% -33.9% 26.0% 73.72%
2020 31.0% -0.7% 180.6% 29.14%
2019 22.0% 4.6% 63.8% 74.81%

NAV & Total Return History


AHSAX - Holdings

Concentration Analysis

AHSAX Category Low Category High AHSAX % Rank
Net Assets 125 M 6.16 M 45 B 72.39%
Number of Holdings 50 23 413 77.91%
Net Assets in Top 10 62.8 M 2.07 M 20.4 B 71.17%
Weighting of Top 10 53.29% 18.1% 77.0% 26.99%

Top 10 Holdings

  1. UNITEDHEALTH GROUP INC 0.00000000 9.28%
  2. HUMANA INC 0.00000000 8.28%
  3. IMPULSE DYNAMICS IRELAND 0.00000000 5.23%
  4. AMGEN INC 0.00000000 4.96%
  5. MCKESSON CORP 0.00000000 4.81%
  6. REGENERON PHARMACEUTICALS 0.00000000 4.59%
  7. ELI LILLY CO 0.00000000 4.30%
  8. VERTEX PHARMACEUTICALS INC 0.00000000 4.23%
  9. CIGNA CORP 0.00000000 4.07%
  10. ABBVIE INC 0.00000000 3.53%

Asset Allocation

Weighting Return Low Return High AHSAX % Rank
Stocks
95.18% 87.17% 106.13% 68.10%
Cash
4.82% 0.00% 32.99% 26.99%
Preferred Stocks
0.00% 0.00% 7.86% 52.15%
Other
0.00% -22.99% 17.73% 49.69%
Convertible Bonds
0.00% 0.00% 0.37% 36.08%
Bonds
0.00% 0.00% 12.39% 38.04%

Stock Sector Breakdown

Weighting Return Low Return High AHSAX % Rank
Healthcare
100.00% 59.26% 100.00% 17.09%
Utilities
0.00% 0.00% 0.00% 29.75%
Technology
0.00% 0.00% 22.69% 33.54%
Real Estate
0.00% 0.00% 5.89% 33.54%
Industrials
0.00% 0.00% 7.02% 33.54%
Financial Services
0.00% 0.00% 1.60% 48.73%
Energy
0.00% 0.00% 0.00% 29.75%
Communication Services
0.00% 0.00% 9.11% 32.91%
Consumer Defense
0.00% 0.00% 25.73% 39.24%
Consumer Cyclical
0.00% 0.00% 1.92% 33.54%
Basic Materials
0.00% 0.00% 7.16% 53.80%

Stock Geographic Breakdown

Weighting Return Low Return High AHSAX % Rank
US
90.79% 66.21% 104.41% 58.28%
Non US
4.39% 0.00% 29.78% 41.10%

AHSAX - Expenses

Operational Fees

AHSAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.13% 0.08% 4.28% 46.01%
Management Fee 0.55% 0.03% 1.25% 20.86%
12b-1 Fee 0.25% 0.00% 1.00% 32.05%
Administrative Fee 0.03% 0.03% 0.25% 5.26%

Sales Fees

AHSAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.25% 3.50% 5.75% 75.00%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

AHSAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% 19.51%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

AHSAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 152.78% 0.00% 238.00% 96.38%

AHSAX - Distributions

Dividend Yield Analysis

AHSAX Category Low Category High AHSAX % Rank
Dividend Yield 0.00% 0.00% 6.98% 53.99%

Dividend Distribution Analysis

AHSAX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual SemiAnnual Annual

Net Income Ratio Analysis

AHSAX Category Low Category High AHSAX % Rank
Net Income Ratio -0.63% -2.54% 1.85% 77.56%

Capital Gain Distribution Analysis

AHSAX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

AHSAX - Fund Manager Analysis

Managers

Daniel Chung


Start Date

Tenure

Tenure Rank

Oct 01, 2005

16.67

16.7%

Dan Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 27 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan is also a member of The Alger Partners Plan. Throughout his tenure at Alger, he has made numerous TV appearances on Bloomberg, CNBC, and Fox Business. Dan has also been featured and quoted frequently in Barron’s, Citywire, Forbes, Investment News, Pensions & Investments, and USA Today. Prior to joining Alger, Dan was an associate at Simpson Thacher & Bartlett LLP in New York City in 1989 while he earned an LL.M. from New York University. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After graduating, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. Dan is also a CFA charterholder and a member of the CFA Institute. Dan currently serves as a board trustee and former chairman of The Nature Conservancy in the State of New York and is a Global Campaign Committee Member of The Nature Conservancy. He is also actively involved with the Stanford in New York Internship Program, and frequently contributes to and supports various charitable organizations including the Harlem Education Activities Fund (HEAF) and Target Margin Theater.

Sanjiv Talwar


Start Date

Tenure

Tenure Rank

Jul 01, 2021

0.92

0.9%

Dr. Sanjiv Talwar is Senior Vice President, Senior Analyst, Portfolio Manager of the Alger Health Sciences and Large Cap Growth strategies and the Head of Healthcare. He joined Alger in 2021 with 15 years of investment experience and more than 12 years of experience in scientific and medical research. Before joining Alger, Sanjiv was a Portfolio Manager, Senior Analyst and Director of Equity Research for Oppenheimer Funds, a life sciences fund from 2012 to 2021 at Invesco, where he also served as a Senior Healthcare Analyst on a global fund. Prior to that, Sanjiv was an Associate Principal at McKinsey & Company from 2006 to 2012, where he led consulting teams focused on healthcare, serving industry and private equity globally.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.84 0.25